Advertisement

Pharmaceutical Research

, Volume 17, Issue 2, pp 154–159 | Cite as

Comparison of Zafirlukast (Accolate®) Absorption After Oral and Colonic Administration in Humans

  • Jeff D. Fischer
  • Min H. Song
  • A. Benjamin Suttle
  • William D. Heizer
  • Charles B. Burns
  • Dennis L. Vargo
  • Kim L. R. Brouwer
Article

Abstract

Purpose. This study characterized the gastrointestinal (GI) absorptionof zafirlukast after oral and colonic administration in humans.

Methods. Five healthy subjects received zafirlukast solution (40 mg)orally and via an oroenteric tube into the colon in a randomized,crossover fashion. Two additional subjects were dosed into the distalileum. Serial blood samples were obtained and plasma concentrationswere quantitated by HPLC.

Results. Mean ± SD pharmacokinetic parameters after oral vs. colonicadministration were: AUC of 2076 ± 548 vs. 602 ± 373 ng*h/mL,respectively, and Cmax of 697 ± 314 vs. 194 ± 316 ng/mL, respectively.Mean colon:oral AUC and Cmax were 0.29 and 0.30, respectively.Median tmax values were 2.0 and 1.35 hr after oral and colonicadministration. First-order absorption rate constants (Ka and Kac) wereestimated from a two-compartment model with first-order elimination.Kac:Ka was <0.5 in 4 of the 5 subjects dosed in the colon.

Conclusions. Zafirlukast was absorbed at multiple sites in the GI tract.The rate and extent of zafirlukast absorption was less after colonicthan oral administration. Zafirlukast was significantly absorbed in thedistal ileum. This study demonstrated that gamma scintigraphy, digitalradiography, and fluoroscopy can be used to track the movement andconfirm the location of the oroenteric tube in the GI tract.

zafirlukast Accolate® absorption colon oroenteric 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    P. Jain and J. A. Golish. Clinical management of asthma in the 1990s. Current therapy and new directions. Drugs. 52 Supplement 6:1-11 (1996).Google Scholar
  2. 2.
    S. L. Spector. Management of asthma with zafirlukast. Clinical experiences tolerability profile. Drugs. 52 Supplement 6:36-46 (1996).Google Scholar
  3. 3.
    P. M. O'Byrne. Leukotrienes in the pathogenesis of asthma. Chest. 111 Supplement 2:27S-34S (1997).Google Scholar
  4. 4.
    Zeneca Pharmaceuticals. Investigational drug brochure for AccolateTM (zafirlukast). 8th edition (1996).Google Scholar
  5. 5.
    R. D. Savidge, K. H. Bui, B. K. Birmingham, J. L. Morse, and R. C. Spreen. Metabolism and excretion of zafirlukast in dogs, rats, and mice. Drug Metab. Dispos. 26:1069-1076 (1998).Google Scholar
  6. 6.
    P. Kerlin, R. Tucker, and S. F. Phillips. Rapid intubation of the ileo-colonic region of man. Aust. N. Z. J. Med. 13:591-593 (1983).Google Scholar
  7. 7.
    M. F. Williams, G. E. Dukes, W. Heizer, Y. H. Han, D. J. Hermann, T. Lampkin, and L. J. Hak. Influence of gastrointestinal site of drug delivery on the absorption characteristics of ranitidine. Pharm. Res. 9:1190-1194 (1992).Google Scholar
  8. 8.
    K. H. Bui, C. M. Kennedy, C. T. Azumaya, and B. K. Birmingham. Determination of zafirlukast, a selective leukotriene antagonist, in human plasma by normal-phase high performance liquid chromatography with fluorescence detection. J. Chrom. 696:131-136 (1997).Google Scholar
  9. 9.
    P. H. Hsyu, J. F. Pritchard, H. P. Bozigian, T. L. Lloyd, R. H. Griffin, R. Shamburek, G. Krishna, and W. H. Barr. Comparison of the pharmacokinetics of an ondansetron solution (8 mg) when administered intravenously, orally, to the colon, and to the rectum. Pharm. Res. 11:156-159 (1994).Google Scholar
  10. 10.
    K. K. Chan, A. Buch, R. D. Glazer, V. A. John, and W. H. Barr. Site-differential gastrointestinal absorption of benazepril hydrochloride in healthy volunteers. Pharm. Res. 11:432-437 (1994).Google Scholar
  11. 11.
    W. H. Barr, E. M. Zola, E. L. Candler, S. M. Hwang, A. V. Tendolkar, R. Shamburek, B. Parker, and M. D. Hilty. Differential absorption of amoxicillin from the human small and large intestine. Clin Pharmacol. Ther. 56:279-285 (1994).Google Scholar
  12. 12.
    K. K. Chan, P. Mojaverian, B. A. Ziehmer, and V. A. John. Application of radiotelemetric technique in evaluating diclofenac sodium absorption after oral administration of various dosage forms in healthy volunteers. Pharm. Res. 7:1026-1032 (1990).Google Scholar
  13. 13.
    T. L. Russell, R. R. Berardi, J. L. Barnett, T. L. O'sullivan, J. G. Wagner, and J. B. Dressman. pH-related changes in the absorp-tion of dipyridamole in the elderly. Pharm. Res. 11:136-143 (1994).Google Scholar
  14. 14.
    S. Mattioli, V. Felice, V. Pilotti, M. L. Bacchi, M. Pastina, and G. Gozzetti. Indications for 24-hour gastric pH monitoring with single and multiple probes in clinical research and practice. Dig. Dis. Sci. 37:1793-1801 (1992).Google Scholar

Copyright information

© Plenum Publishing Corporation 2000

Authors and Affiliations

  • Jeff D. Fischer
    • 1
    • 2
  • Min H. Song
    • 1
  • A. Benjamin Suttle
    • 3
    • 4
  • William D. Heizer
    • 5
  • Charles B. Burns
    • 6
  • Dennis L. Vargo
    • 3
  • Kim L. R. Brouwer
    • 1
    • 7
  1. 1.School of PharmacyUniversity of North CarolinaChapel Hill
  2. 2.Quintiles, Inc.
  3. 3.AstraZenecaWilmington
  4. 4.Glaxo Wellcome Inc.
  5. 5.School of MedicineUniversity of North CarolinaChapel Hill
  6. 6.Department of RadiologyUniversity of North Carolina HospitalsChapel Hill
  7. 7.Division of Drug Delivery and Disposition, School of PharmacyThe University of North CarolinaChapel Hill

Personalised recommendations